| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to compounds of formula I , and pharmaceutically acceptable salts thereof, where L denotes O, S, or CH 2 ; Y denotes N or CH; Z denotes CR 3 ; G denotes CH; R 1 denotes a heteroaryl ring of formula , where D 1 denotes S, O; D 2 denotes N or CR 12 ; D 3 denotes CR 12 ; R 2 denotes (C 6 -C 10 )-aryl; 5-9-member mono- or bicyclic heteroaryl with 1 or 2 heteroatoms independently selected from N or S; a saturated or partially saturated (C 3 -C 7 )-cycloalkyl; or a saturated 5-6-member heteocyclyl with 1 heteroatom selected from N, where said aryl, heteroaryl, cycloalkyl and heterocyclyl are optionally substituted with one or two groups independently selected from (C 1 -C 6 )-alkyl, F, Cl, Br, CF 3 , CN, NO 2 , OR 6 , C(-O)R 6 , C(=O)OR 6 , C(=O)NR 6 R 7 , saturated 6-member heterocyclyl with 2 heteroatoms independently selected from N or O, and S(O) 2 R 6 , and where said alkyl is optionally substituted with one -OR 8 group; R 3 denotes H; (C 1 -C 6 )-alkyl; (C 2 -C 6 )-alkenyl; Cl; Br; OR 6 ; SR 6 ; phenyl; or a 6-member heteroaryl with 1 heteroatom selected from N, where said alkyl and alkenyl are optionally substituted with one group selected from C(=O)OR 8 , -OR 8 , -NR 8 R 9 ; or a saturated 6-member heterocyclyl with 1 heteroatom selected from N or O. n EFFECT: disclosed compounds are used in treating and preventing diseases mediated by insufficient level of glucokinase activity, such as sugar diabetes. n 16 cl, 479 ex |